Non-invasive toluene sensor for early diagnosis of lung cancer

2016 ◽  
Author(s):  
Rahul Saxena ◽  
Sudha Srivastava
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Non Invasive ◽  
Diagnosis Of Lung Cancer

scholarly journals Application of Circulating Genetically Abnormal Cells in the Early-stage Diagnosis of Lung Cancer

2021 ◽  
Author(s):  
xiaochang qiu ◽  
haoran Zhang ◽  
yongheng Zhao ◽  
yunyan Wan ◽  
dezhi Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Detection ◽  
Early Diagnosis ◽  
Lung Disease ◽  
Roc Curve ◽  
Early Detection Of Disease ◽  
Non Invasive ◽  
Imaging Characteristics ◽  
Abnormal Cells ◽  
Diagnosis Of Lung Cancer

Abstract Background Lung cancer is the primary cause of cancer related death worldwide, early detection of the disease contributes to early diagnosis and reduce the incidence of death from lung cancer. Therefore, an effective and non-invasive method for early diagnosis of lung cancer is urgently needed.Methods To evaluate the diagnostic performance of circulating genetically abnormal cells(CAC) in early lung cancer, a total of 63 participants who completed CAC detection by ZHUHAI SANMED BIOTECH INC. and obtained pathological results from January to December 2020 were included in our study, which were divided into 50 cases of lung cancer ,13 cases of benign lung disease. The levels of lung cancer-related markers in peripheral blood and chest computed tomography(CT) imaging characteristics of these patients were collected before pathological acquisition.Results The positive rate of CAC was 90.0% in lung cancer group and 23.1% in benign lung disease group, the difference was statistically significant (P＜0.01).The area under the receiver operating characteristic (ROC) curve of CAC was 0.837, the sensitivity was 90%, and the specificity was 76.9%.The area under the ROC curve and sensitivity were both higher than the combined or single serum tumor marker test.Conclusions This study preliminarily concludes that CAC, as a non-invasive test, has high sensitivity and specificity for early diagnosis of lung cancer, which is expected to help early detection of disease in lung cancer patients and has certain help and guiding significance for clinical work.

scholarly journals Promoting early diagnosis and recovering from the COVID-19 pandemic in lung cancer through public awareness campaigns: learning from patient and public insight work

2021 ◽  
Vol 8 (1) ◽  
pp. e001120
Author(s):  
Matthew Evison ◽  
Sarah Taylor ◽  
Seamus Grundy ◽  
Anna Perkins ◽  
Michael Peake
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Late Stage ◽  
Healthcare Professionals ◽  
Public Awareness ◽  
The Public ◽  
Awareness Campaigns ◽  
The North ◽  
The Common ◽  
Diagnosis Of Lung Cancer

COVID-19 has had a devastating impact on outcomes in lung cancer leading to later stage presentation, less curative treatment and higher mortality. This has amplified the existing problem of late-stage presentation in lung cancer and is a call to arms for a multifaceted strategy to address this, including public awareness campaigns to promote healthcare review in patients with persistent chest symptoms. We report the learning from patient and public insight work from across the North of England exploring the barriers to seeking healthcare review with persistent chest symptoms. Members of the public described how a lack of importance is placed on the common symptoms of lung cancer and a feeling of being unworthy of review by healthcare professionals. They would feel motivated to seek review by dispelling the nihilism of lung cancer and would be able to take action more easily by removing the logistical hassle in the process. We propose a four-pillar framework (validation–endorsement–motivation–action) for developing the content of any public awareness campaigns promoting early diagnosis of lung cancer based on the findings of this comprehensive insight work. All providers and commissioners must work together to overcome the perceived and real barriers to patients with persistent chest symptoms.

Early Diagnosis of Lung Cancer

2010 ◽  
Vol 31 (1) ◽  
pp. 39-47 ◽  
Author(s):  
Kazuhiro Yasufuku
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Diagnosis Of Lung Cancer

scholarly journals Identification of Serological Biomarkers for Early Diagnosis of Lung Cancer Using a Protein Array-Based Approach

2017 ◽  
Vol 16 (12) ◽  
pp. 2069-2078 ◽  
Author(s):  
Jianbo Pan ◽  
Guang Song ◽  
Dunyan Chen ◽  
Yadong Li ◽  
Shuang Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Protein Array ◽  
Diagnosis Of Lung Cancer ◽  
Serological Biomarkers

scholarly journals Breathprinting and Early Diagnosis of Lung Cancer

2018 ◽  
Vol 13 (7) ◽  
pp. 883-894 ◽  
Author(s):  
Gaetano Rocco ◽  
Giorgio Pennazza ◽  
Marco Santonico ◽  
Filippo Longo ◽  
Raffaele Rocco ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Diagnosis Of Lung Cancer

Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-stage Lung Cancer Diagnosis

2020 ◽  
Author(s):  
Lingling Wan ◽  
Yutong He ◽  
Qingyi Liu ◽  
Di Liang ◽  
Yongdong Guo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Cancer Patients ◽  
Early Stage ◽  
Untargeted Metabolomics ◽  
Early Stage Lung Cancer ◽  
Lung Cancer Patients ◽  
Diagnosis Of Lung Cancer ◽  
Metabolomics Analysis ◽  
Stage Lung Cancer

Abstract Background: Lung cancer is a malignant tumor that has the highest morbidity and mortality rate among all cancers. Early diagnosis of lung cancer is a key factor in reducing mortality and improving prognosis. Methods: In this study, we performed CTC next-generation sequencing (NGS) in early-stage lung cancer patients to identify lung cancer-related gene mutations. Meanwhile, a serum liquid chromatography-tandem mass spectrometry (LC-MS) untargeted metabolomics analysis was performed in the CTC-positive patients, and the early diagnostic value of these assays in lung cancer was analyzed. Results: 62.5% (30/48) of lung cancer patients had ≥ 1 CTC. By CTC NGS, we found that > 50% of patients had 4 commonly mutated genes, namely, NOTCH1, IGF2, EGFR, and PTCH1. 47.37% (9/19) patients had ARIDH1 mutations. Additionally, 30 CTC-positive patients and 30 healthy volunteers were subjected to LC-MS untargeted metabolomics analysis. We found 100 different metabolites, and 10 different metabolites were identified through analysis, which may have potential clinical application value in the diagnosis of CTC-positive early-stage lung cancer (AUC > 0.9). Conclusions: Our results indicate that NGS of CTC and metabolomics may provide new tumor markers for the early diagnosis of lung cancer. This possibility requires more in-depth large-sample research for verification.

Algorithm of the use of tumor markers (TM) in the early diagnosis of lung cancer in our health area

2019 ◽  
Vol 493 ◽  
pp. S120
Author(s):  
J. Liró Armenteros ◽  
A. Barco Sánchez ◽  
M. De Toro Crespo ◽  
C. González Rodriguez
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Tumor Markers ◽  
Health Area ◽  
Diagnosis Of Lung Cancer

scholarly journals Symptoms and the early diagnosis of lung cancer

Thorax ◽  
2005 ◽  
Vol 60 (4) ◽  
pp. 268-269 ◽  
Author(s):  
S S Birring
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Diagnosis Of Lung Cancer
Sign in / Sign up

Export Citation Format

Share Document